Safety and efficacy of arterially directed liver therapies in treatment of hepatic metastatic ovarian cancer: A retrospective single-institution study.

Abstract Purpose To evaluate the safety and efficacy of two locoregional therapies (LRT) including hepatic artery embolization (HAE) and transarterial radioembolization (TARE) in treating patients with metastatic ovarian cancer to the liver. Methods From October 2010 to May 2019, the data of 15 consecutive patients (median age, 54 ± 9.8; range, 35-78) with hepatic metastatic ovarian cancer that were treated with either HAE (n = 6, 40%) or TARE (n = 9, 60%) were reviewed. Most common histopathologic type was epithelial ovarian carcinoma (80%). Most common chemotherapy regimens used prior to embolization included carboplatin, paclitaxel, cisplatin, and bevacizumab. Patients received a mean of 4 ± 3 (range 1-9) lines of chemotherapy. All patients with serous carcinoma were platinum-resistant at the time of embolization. Indications for embolization were progression of disease in the liver while receiving chemotherapy in 14 (93.3%) and palliative pain control in 1 patient. Results Overall response rate at 1, 3, and 6 months was 92.4%, 85.6%, and 70%. The median overall survival from the time of LRT was 9 months (95% confidence interval [CI], 4-14 months). Median local tumor progression was 6.4 ± 5.03 months (95% CI, 3.3-9.5). No grade 3-5 adverse events were detected in either group. Conclusion HAE and TARE were well tolerated in patients with metastatic ovarian cancer to the liver and possibly prolong disease control in heavily treated, predominately platinum-resistant patients. Larger numbers are needed to verify these data.